Spaulding Clinical Research has completed a First-In-Human (FIH) study using its dedicated, 12-bed FIH High-Visibility-Unit (HVU). The study was conducted for a biotech sponsor developing a non-opioid analgesic.   Spaulding conducted all dosing, blood draws and procedures at the bedside in its 12-bed, HVU with glass sliding doors and a glass-enclosed central nursing station. Clinical investigators and study staff viewed subjects in their rooms from the nursing station, as well as continuously mo...